中国临床药理学杂志Issue(13)：1230-1232,3.DOI:10.13699/j.cnki.1001-6821.2015.13.003
培美曲塞或吉西他滨联合卡铂治疗晚期非小细胞肺癌的临床疗效及安全性评价
Clinical efficacy and safety of pemetrexed or gemcitabine combined with carboplatin in the treatment of advanced non-small cell lung cancer
摘要
Abstract
Objective To discuss the clinical curative effect and toxicity of pemetrexed or gemcitabine combined with carboplatin in the treatment of advanced non -small cell lung cancer ( NSCLC ) .Methods Eighty patients with advance NSCLC were included in this study and randomly divided into group A and B with 39 and 41 cases in each group.Peme-trexed 500 mg・ m-2 intervenous drop infusion day 1 , carboplatin 5 mg・ mL-1・ min-1 intervenous drop infusion day 1 was administered in group A and gemcitabine 1000 mg・ m-2 intervenous drop infusion day 1 , 8 carboplatin 5 mg・ mL-1・ min -1 intervenous drop infusion day 1 with 21 days per cycle for 4 -6 cycles.The objective response rate ( ORR) and disease control rate ( DCR) , progression free survival ( PFS) and toxicity between group A and group B were compared . Results The ORR, DCR, PFS were 33.33%, 69.23%, 5.8 months in group A and 36.59%, 63.41% 5.5 months in group B with no difference between the two groups ( P >0.05 ) . The grade Ⅲ -Ⅳdigestive tract reaction and bone marrow suppression were 12.8%, 10.3%in group A and 9.8%, 31.7% in group B.The grade Ⅲ-Ⅳbone marrow suppression risk was significant higher in group B than group A.Conclusion The clinical effects was the same for pemetrexed or gemcitabine combined with carboplatin in the treatment of advanced non -small cell lung cancer , but the toxicity in pemetrexed group was less than gemcitabine group .关键词
晚期非小细胞肺癌/培美曲塞/吉西他滨/卡铂/临床疗效/不良反应Key words
advanced non-small cell lung cancer/pemetrexed/gemcitabine/carboplatin/efficacy/toxicity分类
医药卫生引用本文复制引用
冯江,陈立军..培美曲塞或吉西他滨联合卡铂治疗晚期非小细胞肺癌的临床疗效及安全性评价[J].中国临床药理学杂志,2015,(13):1230-1232,3.基金项目
金华市科技基金资助项目 （）
